TIDMLLAI

RNS Number : 2574J

LungLife AI, INC

14 August 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

Director share purchases

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company's common shares of US $0.0001 each ("Common Shares") undertaken by directors.

On 14 August 2023, Paul Pagano, Chief Executive Officer, purchased 7,123 Common Shares at a price of 69.84 pence per share. Following this purchase, Paul Pagano now holds 12,123 Common Shares, representing approximately 0.047% of the outstanding share capital of the Company.

In addition, on 14 August 2023, David Anderson, Chief Financial Officer, purchased 7,123 Common Shares at a price of 69.84 pence per share. Following this purchase, David Anderson now holds 12,123 Common Shares, representing approximately 0.047% of the outstanding share capital of the Company.

For further information please contact:

 
LungLife AI, Inc.                                                            www.lunglifeai.com 
Paul Pagano, CEO                                                                Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                   Tel: +44 (0)20 7597 5970 
 & Joint Broker) 
Virginia Bull / Cameron MacRitchie 
 / Lydia Zychowska 
 
  Goodbody (Joint Broker)                                  Tel: +44 (0) 20 3841 6202 / +353 (1) 
  Tom Nicholson / Stephen Kane                                                         667 0420 
Walbrook PR Limited                       Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Paul McManus / Alice Woodings / Phillip                    Mob: 07980 541 893 / 07407 804 654 / 
 Marriage                                                                         07867 984 082 
 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                               Paul Pagano 
     ---------------------------------  ------------------------------------- 
 2.   Reason for the Notification 
     ------------------------------------------------------------------------ 
 a)   Position/status                    Chief E xecutive Officer 
     ---------------------------------  ------------------------------------- 
 b)   Initial notification/amendment     Initial notification 
     ---------------------------------  ------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------ 
 a)   Name                               LungLife AI, Inc 
     ---------------------------------  ------------------------------------- 
 b)   LEI                                549300VBVDIF0Y3OVI38 
     ---------------------------------  ------------------------------------- 
 4.   Details of the transaction(s):section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv)each place where transactions have been 
       conducted 
     ------------------------------------------------------------------------ 
 a)   Description of the Financial       Common shares of $0.0001 each in the 
       instrument, type of instrument,    capital of the Company 
       identification code 
                                          ISIN: USU5500L1045 
     ---------------------------------  ------------------------------------- 
 b)   Nature of the Transaction          Purchase of Common Shares 
     ---------------------------------  ------------------------------------- 
 c)   Price(s) and volume(s)              Price          Volume 
                                           69.84 pence    12,123 
                                                         ------- 
     ---------------------------------  ------------------------------------- 
 d)        Aggregated information        As above 
             *    Aggregated volume 
 
 
             *    Price 
     ---------------------------------  ------------------------------------- 
 e)   Date of the transaction            14/08/23 
     ---------------------------------  ------------------------------------- 
 f)   Place of the transaction           London Stock Exchange 
     ---------------------------------  ------------------------------------- 
 

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                               David Anderson 
     ---------------------------------  ------------------------------------- 
 2.   Reason for the Notification 
     ------------------------------------------------------------------------ 
 a)   Position/status                    Chief Financial Officer 
     ---------------------------------  ------------------------------------- 
 b)   Initial notification/amendment     Initial notification 
     ---------------------------------  ------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------ 
 a)   Name                               LungLife AI, Inc 
     ---------------------------------  ------------------------------------- 
 b)   LEI                                549300VBVDIF0Y3OVI38 
     ---------------------------------  ------------------------------------- 
 4.   Details of the transaction(s):section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv)each place where transactions have been 
       conducted 
     ------------------------------------------------------------------------ 
 a)   Description of the Financial       Common shares of $0.0001 each in the 
       instrument, type of instrument,    capital of the Company 
       identification code 
                                          ISIN: USU5500L1045 
     ---------------------------------  ------------------------------------- 
 b)   Nature of the Transaction          Purchase of Common Shares 
     ---------------------------------  ------------------------------------- 
 c)   Price(s) and volume(s)              Price          Volume 
                                           69.84 pence    12,123 
                                                         ------- 
     ---------------------------------  ------------------------------------- 
 d)        Aggregated information        As above 
             *    Aggregated volume 
 
 
             *    Price 
     ---------------------------------  ------------------------------------- 
 e)   Date of the transaction            14/08/23 
     ---------------------------------  ------------------------------------- 
 f)   Place of the transaction           London Stock Exchange 
     ---------------------------------  ------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPIMTTMTTBBLJ

(END) Dow Jones Newswires

August 14, 2023 08:32 ET (12:32 GMT)

Lunglife Ai (LSE:LLAI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse Lunglife Ai
Lunglife Ai (LSE:LLAI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse Lunglife Ai